Cancer clinical trials in the region Occitanie

205 currently recruiting clinical trials
Region Occitanie

Phase 2 Lymphoma
#NCT06271057
B cell lymphoma Large B cell lymphoma Primary mediastinal lymphoma Indolent transformed lymphoma > 60 ml/min 2 3 or more
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Liver and bile duct cancer
#NCT05622071
Hepatocellular carcinoma Unhealthy B B C
Transplant Immunotherapy
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
UNICANCER
Phase 2 Lymphoma
#NCT05283720
B cell lymphoma Mantel cell lymphoma CD20 None 1 2 3 or more
Bispecific T-cell engager antibodies
IUCT Oncopôle (Toulouse)
Abbvie
Phase 2 Lymphoma
#NCT05283720
B cell lymphoma Follicular lymphoma CD20 1 2 3 or more
Systemic Treatment-Naive Bispecific T-cell engager antibodies
IUCT Oncopôle (Toulouse)
Abbvie
Phase 2 Lymphoma
#NCT05283720
B cell lymphoma Large B cell lymphoma Indolent transformed lymphoma CD20 None 1 2 3 or more
Bispecific T-cell engager antibodies
IUCT Oncopôle (Toulouse)
Abbvie
Phase 2 Lymphoma
#NCT03930953
B cell lymphoma 2 3 or more
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
Celgene
Phase 2 Lymphoma
#NCT04802590
B cell lymphoma Mantel cell lymphoma None CD20 > 60 ml/min 50-60 ml/min None Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Breast cancer
#NCT05386108
HER2 Negative HR Positive Metastatic Chemotherapy Hormone therapy Targeted therapy
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre de Cancérologie du Grand Montpellier (Montpellier)
Stemline Therapeutics, Inc.
Phase 2 Breast cancer
#NCT04666961
HR Positive Localized Systemic Treatment-Naive
BRCA 1/2
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier)
Institut de Cancérologie de l'Ouest
Phase 1 / Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer
#NCT06162221
Locally Advanced Metastatic KRAS G12C
Systemic Treatment-Naive Systemic Treatment-Naive
IUCT Oncopôle (Toulouse)
Revolution Medicines, Inc.